MAPT and Alzheimer disease: Against the backdrop of this setting, Jack and colleagues proposed a new bio-diagnostic hallmark of AD neuropathology, namely, beta-amyloid deposition, phosphorylated tau and neurodegeneration (Jack et al., 2018).